secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001193125-23-028869
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca extends cash runway to H2 2025, accelerates naporafenib and ERAS-601 readouts
--------------------------------------------------------------------------------

- Cash runway extended from H1 2025 to H2 2025; resources focused on naporafenib and ERAS-007/601 sub-studies.
- SEACRAFT-1 (naporafenib in RAS Q61X solid tumors) data readout accelerated to Q2-Q4 2024 from H2 2024-H1 2025.
- FLAGSHP-1 (ERAS-601 in HPV-neg HNSCC) data readout accelerated to H1 2024 from calendar year 2024.
- HERKULES-3 (ERAS-007/601 in BRAFm CRC) data readout affirmed for H2 2023-H1 2024.
- Other milestones: SEACRAFT-2 Ph3 FPD in NRASm melanoma H1 2024, THUNDERBBOLT-1 Ph1 data in rGBM H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312523028869/0001193125-23-028869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312523028869/d382775d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-028869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer